Thursday, April 16, 2026
35.2 C
Bengaluru

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the "Top Line": India’s domestic market...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

FieldForce Is Not Your Frontline Anymore. Meet the New Force in Healthcare

When drones first appeared on battlefields, military establishments reacted...

Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality

Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed...

Topics

Don't Miss MedicinMan Updates

Hot this week

Antibody-Drug Conjugates (ADCs): The Disruptors Leading Oncology’s Gold Rush in 2025

1. Market Overview The oncology sector remains the most dominant...

Blinkit, Zepto, Instamart: Who Will Own India’s At‑Home Diagnostics Market?

India’s diagnostics market is undergoing a quiet but profound...
spot_img

Follow Us

Popular Categories

Video Insights

spot_imgspot_img

Headlines

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the "Top Line": India’s domestic market at $25 billion (₹2.12 lakh...

Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution

In the blistering Sonoran Desert, where temperatures regularly exceed 100 degrees Fahrenheit, a sluggish, beaded lizard emerges from its...

Exclusive Articles

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the "Top Line": India’s domestic market at $25 billion (₹2.12 lakh...

Music

Oracle Debacle – Midlife Reinvention is an Al Generated Orwellian Lie

A Tale of Two Truths: Severance, Up in the...

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Food

Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales

Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...

Trump’s 100% Drug Tariffs Explained: The Surprising Opportunity for India

How the 2026 U.S. tariff action on branded drugs...

Can Eli Lilly Outrun the Same-Glutide Stampede with Tirzepatide and Orforglipron?

The "aspirinization" of obesity—moving from a niche, high-cost injectable...

IPM February 2026: Market Intelligence Report

Executive Summary The Indian Pharmaceutical Market (IPM) sustained its growth...

Samuel Paradise

Manuela Cole

Keisha Adams

George Pharell

spot_imgspot_img

Leaders Speak

Business leaders sharing their insights

K. Hariram
8 POSTS
Raja Reddy
5 POSTS